Canaccord Genuity maintains Aclaris Therapeutics at Buy, raises price target to $13 from $10
Canaccord Genuity reaffirmed its Buy rating for Aclaris Therapeutics and increased its price target to $13 from $10, representing a 30% increase. This target suggests a 227.5% upside from the Oct 30 closing price of $3.97.
How this was made

The 30-second read
Why it matters
Analyst price‑target upgrades can move thinly‑traded stocks, but the effect is often short‑lived without substantive catalyst.
Market read
A modest analyst upgrade with a higher price target may generate modest buying interest.
What to watch
No new clinical data or regulatory events accompany the upgrade.
Background
Aclaris Therapeutics is a small-cap biotech listed on NASDAQ.
Ticker impact
Canaccord Genuity raised its price target on Aclaris Therapeutics to $13 from $10.
potential upward pressure as the market prices in the higher target
The new target implies a 227% upside from the recent close, which could prompt short-covering and buying.
Market effects
May boost sentiment in the biotech sector.
Limited to US biotech investors.
Minimal global impact.
Counterpoint
The target raise could be overly optimistic given the company's cash burn.
Key entities
- AnalystCanaccord Genuity
Equity research firm that issued the rating.
- CompanyAclaris Therapeutics
Biopharmaceutical company focused on dermatology and oncology.

